We bring you the latest news from the healthcare about the health care in the United Kingdom. Do your have news for us? Contact the editor. Watch also this special movie.

maandag 20 maart 2017

Nature Reviews Clinical Oncology - Table of Contents alert Volume 14 Issue 4

If you are unable to see the message below, click here to view.

Nature Reviews Clinical Oncology

Leukaemia and Lymphoma
June 10-13, 2017
Ascona, Switzerland

Registrations will be processed on a first-come/first-served basis.

Participants' profile
Designed for postgraduate medical doctors interested in haematological oncology. A mix of experienced clinicians or pathologists etc., scientists (PhD) and oncology/haematology trainees is welcome.

Click here for more information
April 2017 Volume 14 Number 4Advertisement
Nature Reviews Clinical Oncology cover
2015 2-year Impact Factor 18.786 Journal Metrics 2-year Median 11
In this issue
Research Highlights
News and Views

Also this month
 Featured article:
PD-1–PD-L1 immune-checkpoint blockade in B-cell lymphomas
Aaron Goodman, Sandip P. Patel & Razelle Kurzrock

Key Advances in Medicine eBook from Nature Reviews - FREE to download! 

This essential resource summarizes the groundbreaking clinical and biomedical discoveries of 2016 and highlights the trends to watch out for in 2017, making it a must read eBook for anyone with an interest in medical science. 

Download for free

Recommend to library
nature.com webcasts

Join us for our upcoming webcast followed by live Q&A:

Presented by BioPharma Dealmakers

Date: Wednesday, March 29, 2017
Time: 8AM PDT | 11AM EDT | 4PM BST | 5PM CEST


Sponsored by: Corium International | Portal Instruments Inc. | TissueGen Inc. | TrioxNano
Comment: Drugs that lack single-agent activity: are they worth pursuing in combination?
Bishal Gyawali & Vinay Prasad
Published online: 07 March 2017
p193 | doi:10.1038/nrclinonc.2017.27

Over the past decade, many anticancer drugs have been approved for use only in combination regimens and only in palliative settings, despite having negligible single-agent activity in the same disease. We examine whether these agents provide any tangible clinical benefits and are worthy of continued development, or whether R&D efforts would be better focused elsewhere.
Full Text | PDF | Supplementary information

Comment: Getting real about NCI-designated Cancer Center advertising
David Rubenson & Daniel S. Kapp
Published online: 07 March 2017
p195 | doi:10.1038/nrclinonc.2017.28

The 69 National Cancer Institute-designated Cancer Centers are premier academic institutions that place significant value on research integrity and an ethic that rigorous evidence should guide patient care and define expectations. Recent patient-focused advertising has strayed from these values, obscuring valid reasons for seeking care at these centres.
Full Text | PDF


Urological cancer: Unravelling intertwined second-line options
Published online: 20 March 2017
p197 | doi:10.1038/nrclinonc.2017.38


Immunotherapy: Start your engineering — CARs take to the TRAC
Published online: 20 March 2017
p198 | doi:10.1038/nrclinonc.2017.39


Haematological cancer: Idelalisib for CLL — risky benefit
Published online: 14 February 2017
p199 | doi:10.1038/nrclinonc.2017.17


Breast cancer: Utidelone: burden relief in pretreated women
Published online: 02 March 2017
p199 | doi:10.1038/nrclinonc.2017.29


Targeted therapy: Leveraging ADCC to enhance anti-HER2 therapy
Published online: 14 February 2017
p200 | doi:10.1038/nrclinonc.2017.19


Gynaecological cancer: SLN staging for endometrial cancer
Published online: 21 February 2017
p200 | doi:10.1038/nrclinonc.2017.25


Targeted therapies: Ibrutinib: new option for relapsed MZL
Published online: 20 March 2017
p200 | doi:10.1038/nrclinonc.2017.26



Lung cancer: Ceritinib is superior to frontline chemotherapy | Pancreatic cancer: Addition of capecitabine prolongs overall survival | Head and neck cancer: Buparlisib is an effective second-line treatment

Nature Reviews Clinical Oncology
JOBS of the week
Full Professorship (W3) for Translational Radiation Oncology
German Cancer Research Center (DKFZ).
Clinical Fellow, Cancer Immunotherapy
Fred Hutchinson Cancer Research Center
Director, Four Diamonds Epigentics and Gene Regulation Research Program in Pediatric Oncology
Penn State Hershey Children's Hospital
Post-Doc Fellow Research / Hem Onc
Children's Hospital Los Angeles
Postdoctoral Position in Cancer Immunology / Immunotherapy
Biomedicine, University Hospital Basel
More Science jobs from
Nature Reviews Clinical Oncology
8th International Conference on Blood and Oncology Research
London, UK
More science events from
Targeted therapies: Remembrance of things past — discontinuation of second-generation TKI therapy for CML
Timothy P. Hughes & David M. Ross
Published online: 07 February 2017
p201 | doi:10.1038/nrclinonc.2017.11
Data from the recent Stop 2G-TKI study confirm that around 60% of patients with chronic myeloid leukaemia who discontinue second-generation BCR-ABL1 tyrosine-kinase inhibitor (TKI) therapy after a sustained deep molecular response remain in remission for longer than 1 year. Importantly, the interim findings suggest that prior response to first-line TKI treatment might predict relapse risk after treatment discontinuation.
Full Text | PDF

nature.com webcasts

Circulating Tumour Cells: Liquid biopsy by high-throughput, high-resolution imaging flow cytometry

Date: Tuesday, March 28, 2017
Time: 8AM PDT | 11AM EDT | 4PM BST | 5PM CEST

Register for FREE

Sponsored by:

Merck KGaA, Darmstadt, Germany.
he life science business of Merck KGaA, Darmstadt, Germany operates as MilliporeSigma in the U.S. and Canada 
PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas
Aaron Goodman, Sandip P. Patel & Razelle Kurzrock
Published online: 02 November 2016
p203 | doi:10.1038/nrclinonc.2016.168
Immune-checkpoint inhibitors are revolutionizing the treatment of many types of solid cancer. Expression of the inhibitory immune-checkpoint proteins programmed cell-death 1 (PD-1) and its ligands (PD-L1 and PD-L2) are frequently detected in haematological malignancies, and agents targeting these proteins have activity in such diseases, notably Hodgkin lymphoma. Herein, the current evidence supporting the roles of PD-1-PD-L1 blockade in the treatment of various B-cell malignancies is reviewed.
Abstract | Full Text | PDF | Supplementary information

Systemic, perioperative management of muscle-invasive bladder cancer and future horizons
Samuel A. Funt & Jonathan E. Rosenberg
Published online: 22 November 2016
p221 | doi:10.1038/nrclinonc.2016.188
In this Review, the authors describe the developing therapeutic landscape for patients with muscle-invasive bladder cancer. In particular, the data supporting the use of neoadjuvant cisplatin-based chemotherapy as a standard of care, the potential impact of genomic profiling on treatment approaches, and the emerging importance of immunotherapy are discussed.
Abstract | Full Text | PDF

From tumour heterogeneity to advances in precision treatment of colorectal cancer
Cornelis J. A. Punt, Miriam Koopman & Louis Vermeulen
Published online: 06 December 2016
p235 | doi:10.1038/nrclinonc.2016.171
Recent advances in molecular biology and our understanding of the development of colorectal cancer (CRC) has enabled the more-precise use of innovative targeted therapies for this disease. In particular, large databases to capture and store genomic information on causative genes frequently deregulated in CRC, the use of gene-expression profiling to differentiate the subtypes of CRC into prognostic and predictive groups, and results from next-generation sequencing analyses have led to an appreciation of the extensive intratumour heterogeneity of this disease. The authors highlight these advances, place them into clinical context, and present other novel targets and therapeutic opportunities on the horizon.
Abstract | Full Text | PDF

Cancer Evolution Collection

This collection highlights the most recent research and review articles published on this topic.
Produced with support from
Activating autophagy to potentiate immunogenic chemotherapy and radiation therapy
Lorenzo Galluzzi et al.
Published online: 15 November 2016
p247 | doi:10.1038/nrclinonc.2016.183
Autophagy is fundamental to cellular homeostasis and also has a central role in the development and progression of cancer. However, autophagy is also required for optimal immune system function, including the development of an anticancer immune response. In this Perspective, the authors present the available preclinical and clinical evidence that autophagy might enhance the effectiveness of both immunogenic chemotherapy and radiotherapy, as opposed to the general view of inhibition of autophagy as an antitumour strategy.
Abstract | Full Text | PDF

nature events
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here.

Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com
More Nature Events
*Nature Reviews Clinical Oncology was previously published as Nature Clinical Practice Oncology.

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount
(You will need to log in to be recognised as a nature.com registrant).

For further technical assistance, please contact our registration department

For print subscription enquiries, please contact our subscription department

For other enquiries, please contact our feedback department

Nature Publishing Group | One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA

Nature Publishing Group's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne
San Diego - San Francisco - Washington - New York - Boston

Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW.

© 2017 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.

nature publishing group